Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

다국어 초록 (Multilingual Abstract)

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR- 2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients with stage IV sarcoma who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were progression-free survival rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12.
Treatment-related adverse effects (AEs) were evaluated. Fifty-nine patients were assessed for efficacy and 64 patients for AEs. The median PFS was 7.93 months. At 12 weeks, the PFR was 74%, the ORR was 16.95% (10/59), and the DCR was 86.44% (51/59). The final ORR was 15.25% (9/59) and the DCR was 57.63% (34/59). Notably, 22 patients (34.38%) who developed hypertension, hand-foot-skin reaction, or proteinuria had significantly longer OS than those without these AEs (18.20 vs. 10.73 months; P = 0.002). We conclude that apatinib is effective and well tolerated in patients with advanced sarcoma. The development of hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorable prognosis, representing a novel finding in sarcoma patients.

참고문헌 (Reference)

1 Tian, S., "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo" 102 : 1374-1380, 2011

2 Kampmann, E., "VEGFR2 predicts decreased patients survival in soft tissue sarcomas" 211 : 726-730, 2015

3 Italiano, A., "Trends in survival for patients with metastatic soft-tissue sarcoma" 117 : 1049-1054, 2011

4 Zucali, P. A., "The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas" 26 : 175-181, 2008

5 Federman, N., "The multidisciplinary management of osteosarcoma" 10 : 82-93, 2009

6 Burningham, Z., "The epidemiology of sarcoma" 2 : 14-, 2012

7 Lamplot, J. D., "The current and future therapies for human osteosarcoma" 9 : 55-77, 2013

8 Balasubramanian, L., "Targeting angiogenesis for the treatment of sarcoma" 18 : 354-359, 2006

9 Riedel, R. F., "Systemic therapy for advanced soft tissue sarcomas : highlighting novel therapies and treatment approaches" 118 : 1474-1485, 2012

10 Ji, G., "Successful treatment of angiosarcoma of the scalp with apatinib : a case report" 9 : 4989-4992, 2016

11 Ji, G., "Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib : a case report" 9 : 643-647, 2016

12 Grignani, G., "Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a nonrandomised phase 2 clinical trial" 16 : 98-107, 2015

13 von Mehren, M., "Soft tissue sarcoma, version 2.2014" 12 : 473-483, 2014

14 Dong, M., "Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a smallmolecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case report" 95 : e4368-, 2016

15 Sun, Y., "Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors" 9 : 105-, 2016

16 Li, J., "Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies" 10 : 529-, 2010

17 Chi, Y., "Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma" 24 : 5233-5238, 2018

18 Yang, W., "Response of advanced soft tissue sarcoma to apatinib : a retrospective analysis" 35 : e22502-e22502, 2017

19 Li, J., "Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction" 34 : 1448-14454, 2016

20 Schwartz, L. H., "RECIST 1.1-update and clarification: from the RECIST committee" 62 : 132-137, 2016

21 Zhang, S., "Problematic analysis and inadequate toxicity data in phase III apatinib trial in gastric cancer" 34 : 3821-, 2016

22 Maki, R. G., "Phase II study of sorafenib in patients with metastatic or recurrent sarcomas" 27 : 3133-3140, 2009

23 Sleijfer, S., "Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group(EORTC study 62043)" 27 : 3126-3132, 2009

24 Heudel, P., "Pazopanib for the treatment of soft-tissue sarcoma" 4 : 65-70, 2012

25 van der Graaf, W. T., "Pazopanib for metastatic soft-tissue sarcoma(PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial" 379 : 1879-1886, 2012

26 Endo, M., "Pazopanib for metastatic soft-tissue sarcoma" 380 : 801-, 2012

27 Nishida, T., "Pazopanib for both GIST and soft-tissue sarcoma" 17 : 549-550, 2016

28 Bramwell, V. H., "Pazopanib and the treatment palette for soft-tissue sarcoma" 379 : 1854-1856, 2012

29 Eisenhauer, E. A., "New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)" 45 : 228-247, 2009

30 Therasse, P., "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 : 205-216, 2000

31 George, S., "Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas" 27 : 3154-3160, 2009

32 Hu, X., "Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer" 135 : 1961-1969, 2014

33 Helman, L. J., "Mechanisms of sarcoma development" 3 : 685-694, 2003

34 Longhi, A., "Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma" 18 : 737-744, 2007

35 Lee, H. J., "Is treatment-emergent toxicity a biomarker of efficacy of apatinib in gastric cancer?" 34 : 3823-, 2016

36 Tang, J. R., "Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor" 287 : L344-L351, 2004

37 Allemani, C., "Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)" 385 : 977-1010, 2015

38 Baird, K., "Gene expression profiling of human sarcomas : insights into sarcoma biology" 65 : 9226-9235, 2005

39 Hensley, M. L., "Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial" 20 : 2824-2831, 2002

40 Zhu, B., "Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma : an observational study" 19 : 198-204, 2018

41 Li, F., "Efficacy and safety of Apatinib in stage IV sarcomas : experience of a major sarcoma center in China" 8 : 64471-66448, 2017

42 Shi, C., "Effective treatment of apatinib in desmoplastic small round cell tumor : a case report and literature review" 18 : 338-, 2018

43 Yan, P., "Effective apatinib treatment of pleomorphic liposarcoma : a case report" 96 : e7771-, 2017

44 Liu, X., "Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib : a cohort study" 10 : 153-, 2017

45 Kumar, S., "Doxorubicininduced cardiomyopathy 17 years after chemotherapy" 39 : 424-427, 2012

46 Siegel, R. L., "Cancer statistics, 2018" 68 : 7-30, 2018

47 Chen, W., "Cancer statistics in China, 2015" 66 : 115-132, 2016

48 Trotti, A., "CTCAEv3.0: development of a comprehensive grading system for the adverse effects of cancer treatment" 13 : 176-181, 2003

49 Mi, Y. J., "Apatinib(YN968D1)reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters" 70 : 7981-7991, 2010

50 Liu, K., "Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma" 8 : e3015-, 2017

51 Zheng, B., "Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3" 495 : 1695-1701, 2018

52 Li, J., "Apatinib for chemotherapy-refractory advanced metastatic gastric cancer : results from a randomized, placebo-controlled, parallel-arm, phase II trial" 31 : 3219-3225, 2013

53 Xie, L., "Apatinib for advanced sarcoma : results from multiple institutions’off-label use in China" 18 : 396-, 2018

54 Li, F., "Apatinib as targeted therapy for sarcoma" 9 : 24548-24560, 2018

55 Roviello, G., "Apatinib : A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer" 372 : 187-191, 2016

56 Tong, X. Z., "Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells" 83 : 586-597, 2012

57 Folkman, J., "Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action" 312 : 594-607, 2006

58 Blay, J. Y., "Advanced soft-tissue sarcoma : a disease that is potentially curable for a subset of patients treated with chemotherapy" 39 : 64-69, 2003

59 Zhou, Y., "Advanced alveolar soft part sarcoma responds to apatinib" 8 : 50314-50322, 2017

60 Zhou, Y., "A case report of apatinib in treating osteosarcoma with pulmonary metastases" 96 : e6578-, 2017